Frankfurt - Delayed Quote EUR

Cosmo Pharmaceuticals N.V. (C43.F)

66.50

-1.00

(-1.48%)

As of 8:32:33 AM GMT+1. Market Open.

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7 million (unaudited), marking a 186% increase compared to 2023. Financial Strength: Year-end cash ...

Newsfile 18 days ago

CMOPF
Cosmo Pharmaceuticals Appoints Chief Strategy Officer

Dublin, Ireland--(Newsfile Corp. - December 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company's focus on strategy-led growth and innovation. She will be reporting to the CEO. ...

Newsfile last month

CMOPF
Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGM

Dublin, Ireland--(Newsfile Corp. - October 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) shareholders today approved the proposal by the Board of Directors to appoint Deloitte Accountants B.V. as new independent auditor of the Company for the financial year ending on 31 December 2024. Cosmo’s previous auditor ...

Newsfile 3 months ago

CMOPF
Cosmo Pharmaceuticals Appoints New Chief Financial Officer

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - October 11, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has ...

Newsfile 3 months ago

CMOPF
Cosmo Pharmaceuticals NV (CMOPF) (H1 2024) Earnings Call Highlights: Revenue Surge and ...

Cosmo Pharmaceuticals NV (CMOPF) reports a remarkable revenue increase and strengthens its position with strategic alliances and innovative advancements.

GuruFocus.com 3 months ago

COPN.SW
-0.46%
MDT
Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development

Dublin, Ireland--(Newsfile Corp. - September 23, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosmo. With extensive experience in expanding global business operations and ...

Newsfile 4 months ago

CMOPF
Cosmo Pharmaceuticals Highlights Study Published in "The Lancet" Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures

Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a landmark study in “The Lancet”. This study, titled “Polyp detection with colonoscopy assisted by ...

Newsfile 4 months ago

CMOPF
Cosmo Intelligent Medical Devices Unveils Next Generation GI Genius(TM) Hardware with New FDA Clearance

Dublin, Ireland--(Newsfile Corp. - July 31, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) focused on pioneering medical devices powered by Artificial Intelligence, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the next generation GI Genius™ hardware, the latest development ...

Newsfile 5 months ago

CMOPF
Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its 2024 half year results. Key highlights ...

Newsfile 6 months ago

CMOPF
Invitation to Cosmo's Half-Year 2024 Webcast on 24 July 2024

Dublin, Ireland--(Newsfile Corp. - July 9, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Half-Year 2024 results on Wednesday, 24 July 2024 at 07:00 am CEST. Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast presentation ...

Newsfile 6 months ago

CMOPF
Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting

Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of 90% versus last year Shareholders approved all other proposals of the Board of Directors, including the adoption of ...

Newsfile 6 months ago

CMOPF
Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China

Dublin, Ireland--(Newsfile Corp. - June 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported that its partner and exclusive licensee of Lumeblue® (Methylene Blue MMX®) for China, China Medical System Holdings Limited (“CMS”) (SEHK: 867), has received the approval for the innovative product in the territory by the National Medical Products Administration of China (NMPA) ...

Newsfile 7 months ago

CMOPF
Cosmo to Bring Real-Time AI into Intelligent Medical Devices with NVIDIA IGX

Dublin, Ireland--(Newsfile Corp. - June 3, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) with its Cosmo Intelligent Medical Devices division (“Cosmo IMD”) is consolidating its strategy to accelerate the adoption of responsible and regulated AI in healthcare, obtaining pragmatic results in its mission to address unmet clinical needs and improve patient outcomes. ...

Newsfile 7 months ago

CMOPF
Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - May 31, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its final audited results for the financial year 2023. Financial highlights ...

Newsfile 7 months ago

CMOPF
Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting

Dublin, Ireland--(Newsfile Corp. - May 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that its shareholders approved all agenda items at today's annual general meeting of shareholders. A total of 7,417,916 ordinary shares in the share capital of Cosmo were represented at this annual general meeting of shareholders ...

Newsfile 7 months ago

CMOPF
Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced that the company has been granted extension until 31 May 2024 to publish its 2023 annual report and to file such report with SIX Exchange Regulation AG. ...

Newsfile 8 months ago

CMOPF
Cosmo Announces Leadership Changes

Ad hoc announcement pursuant to Art. 53 LR Giovanni Di Napoli appointed as new CEO effective from 24 May 2024. Current CEO Alessandro Della Chà to be appointed ...

Newsfile 8 months ago

CMOPF
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care

Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system ...

Newsfile 9 months ago

CMOPF
Bullish: Analysts Just Made A Massive Upgrade To Their Cosmo Pharmaceuticals N.V. (VTX:COPN) Forecasts

Shareholders in Cosmo Pharmaceuticals N.V. ( VTX:COPN ) may be thrilled to learn that the analysts have just delivered...

Simply Wall St. 9 months ago

COPN.SW
-0.46%
Cosmo Pharmaceuticals N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Cosmo Pharmaceuticals N.V. ( VTX:COPN ) just released its latest annual report and things are not looking great. The...

Simply Wall St. 10 months ago

COPN.SW
-0.46%

Performance Overview

Return	C43.F	MSCI WORLD
YTD	-1.48%	+2.54%
1-Year	+4.43%	+18.57%
3-Year	+34.38%	+27.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cosmo Pharmaceuticals N.V. (C43.F)

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Cosmo Pharmaceuticals Appoints Chief Strategy Officer

Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGM

Cosmo Pharmaceuticals Appoints New Chief Financial Officer

Cosmo Pharmaceuticals NV (CMOPF) (H1 2024) Earnings Call Highlights: Revenue Surge and ...

Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development

Cosmo Pharmaceuticals Highlights Study Published in "The Lancet" Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures

Cosmo Intelligent Medical Devices Unveils Next Generation GI Genius(TM) Hardware with New FDA Clearance

Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance

Invitation to Cosmo's Half-Year 2024 Webcast on 24 July 2024

Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting

Cosmo's Oral Diagnostic Drug Lumeblue(R) Receives Approval of New Drug Application in China

Cosmo to Bring Real-Time AI into Intelligent Medical Devices with NVIDIA IGX

Cosmo Reports Excellent Final Full Year 2023 Financial Results - Increases Operating Profit Guidance for 2024 - Dividend of 2.00 per Share Will Be Proposed at EGM on 5 July 2024

Cosmo Pharmaceuticals' Shareholders Approve All Agenda Items at Annual General Meeting

Cosmo Has Received Approval of an Extension in Respect of the Publication and the Filing of Its Annual Report 2023

Cosmo Announces Leadership Changes

Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care

Bullish: Analysts Just Made A Massive Upgrade To Their Cosmo Pharmaceuticals N.V. (VTX:COPN) Forecasts

Cosmo Pharmaceuticals N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Performance Overview